The phase 2 trial KEYNOTE-010 demonstrated the superiority in OS of Pembrolizumab compared to Docetaxel in NSCLC with PD-L1 TPS ≥ 1%, also in patients aged ≥65 years (HR 0.80, 95% CI 0.60–1.01). Here, CD274 is linked to non-small cell lung carcinoma.